|CNAT -- USA Stock|| |
USD 4.99 0.02 0.40%
Co-Founder, CEO and President and Director
Dr. Steven J. Mento, Ph.D., is appointed as President, Chief Executive Officer, Director of Conatus Pharmaceuticals Inc. He is one of cofounders and has served as President and Chief Executive Officer and as a member of board of directors since July 2005. From July 2005 until December 2012, he also served as chairman of the board of directors. He has over 30 years of combined experience in the biotechnology and pharmaceutical industries. From 1997 to 2005, he was President, Chief Executive Officer and a member of the Board of Directors of Idun Pharmaceuticals, Inc. He guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer Inc. Previously, he served as President of Chiron Viagene, Inc., and Vice President of Chiron Corporationrationration from 1995 to 1997. He was Vice President of RD at Viagene from 1992 to 1995. Prior to Viagene, he held various positions at American Cyanamid Company from 1982 to 1992. His last position was Director of Viral Vaccine Research and Development at LederlePraxis Biologicals, a business unit of American Cyanamid. He serves on the boards of directors of BIOCOM, the Biotechnology Industry Organization, BIO Emerging Company Section Governing Body, BIO Health Section Governing Body, Sangamo Biosciences, Inc., and various academic and charitable organizations
Age: 64 CEO Since 2017
Mento holds a B.A. in Microbiology from Rutgers College, and an M.S. and Ph.D. both in Microbiology from Rutgers University.
The company has return on total asset (ROA)
of (14.76) %
which means that it has lost $14.76 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (87.78) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 13.34 M in liabilities with Debt to Equity (D/E) ratio of 57.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Conatus Pharmaceuticals has Current Ratio of 2.36 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. The company was founded in 2005 and is headquartered in San Diego, California. Conatus Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 33 people.Conatus Pharmaceuticals (CNAT) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 33 people. Conatus Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Conatus Pharmaceuticals Leadership Team
|Edward Smith, President, MBA|
|Michelle Vandertie, Executive|
|Dan Kisner, Director|
|James Scopa, Director|
|Steven Mento, CEO|
|Daniel Kisner, Director|
|Preston Klassen, Director|
|David Hale, Chairman|
|Harold Wart, Director, Ph.D|
|William LaRue, Director, MBA|
|Alfred Spada, Founder, Ph.D|
|Charles Cashion, President, MBA|
|Daniel Ripley, President, MBA|
|Keith Marshall, President, MBA|
|Louis Lacasse, Director, MBA|
|Shahzad Malik, Director|
|David Hagerty, President|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Conatus Pharmaceuticals. What is your opinion about investing in Conatus Pharmaceuticals? Are you bullish or bearish?
and pair trading evaluation for Conatus Pharmaceuticals and NantKwest
. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return